{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:07:53Z","timestamp":1767917273302,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biomaterials.2025.123347","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T17:57:37Z","timestamp":1744739857000},"page":"123347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Albumin nanocomplex of BCL-2\/xL inhibitor reduced platelet toxicity and improved anticancer efficacy in myeloproliferative neoplasm and lymphoma"],"prefix":"10.1016","volume":"322","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6221-7462","authenticated-orcid":false,"given":"Hongxiang","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-6408","authenticated-orcid":false,"given":"Chengyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6241-0855","authenticated-orcid":false,"given":"Jizhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6089-9556","authenticated-orcid":false,"given":"Qiuxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-147X","authenticated-orcid":false,"given":"Fang","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5233-3734","authenticated-orcid":false,"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-2126","authenticated-orcid":false,"given":"Duxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2025.123347_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family Reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biomaterials.2025.123347_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib4","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2\u2013family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123347_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","author":"Roberts","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.biomaterials.2025.123347_bib6","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2025.123347_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biomaterials.2025.123347_bib8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib9","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172655","article-title":"Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy","volume":"862","author":"Suvarna","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41419-021-04042-7","article-title":"Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2\/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2\/STAT3\/MCL-1 signaling pathway","volume":"12","author":"Luo","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biomaterials.2025.123347_bib12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","article-title":"First-in-Human study with preclinical data of BCL-2\/BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors","volume":"30","author":"Lakhani","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2025.123347_bib13","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2021-149530","article-title":"Dual BCL-2\/BCL-XL inhibitor pelcitoclax (APG-1252) overcomes intrinsic and acquired resistance to venetoclax in multiple myeloma cells","volume":"138","author":"Yamamoto","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123347_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099404","article-title":"BM-1197: a novel and specific Bcl-2\/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo","volume":"9","author":"Bai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2025.123347_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0959-8049(14)70464-2","article-title":"338 BM-1252 (APG-1252): a potent dual specific Bcl-2\/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity","volume":"50","author":"Bai","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biomaterials.2025.123347_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120910","article-title":"Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation","volume":"275","author":"Luan","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2025.123347_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.101008","article-title":"Progress, challenges, and future of nanomedicine","volume":"35","author":"Zhang","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.biomaterials.2025.123347_bib18","doi-asserted-by":"crossref","first-page":"12281","DOI":"10.1021\/acsnano.9b09713","article-title":"What went wrong with anticancer nanomedicine design and how to make it right","volume":"14","author":"Sun","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2025.123347_bib19","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1080\/17425247.2016.1193149","article-title":"Albumin nanostructures as advanced drug delivery systems","volume":"13","author":"Karimi","year":"2016","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.biomaterials.2025.123347_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/157489209789206869","article-title":"Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery","volume":"4","author":"Fu","year":"2009","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.biomaterials.2025.123347_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl3649","article-title":"Albumin nanoparticle containing a PI3K\u03b3 inhibitor and paclitaxel in combination with \u03b1-PD1 induces tumor remission of breast cancer in mice","volume":"14","author":"Song","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2025.123347_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2326-6066.CIR-16-0125","article-title":"Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer","volume":"5","author":"Cullis","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biomaterials.2025.123347_bib23","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of Albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123347_bib24","article-title":"Albumin-based drug delivery: harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol Cell Ther"},{"key":"10.1016\/j.biomaterials.2025.123347_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jconrel.2011.09.069","article-title":"Impact of albumin on drug delivery \u2014 new applications on the horizon","volume":"157","author":"Elsadek","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2025.123347_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"key":"10.1016\/j.biomaterials.2025.123347_bib27","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41565-021-00897-1","article-title":"Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-Mutant cancer","volume":"16","author":"Li","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejpb.2023.10.022","article-title":"Challenges of nanoparticle albumin bound (nab\u2122) technology: comparative study of abraxane\u00ae with a newly developed albumin-stabilized itraconazole nanosuspension","volume":"193","author":"Adick","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biomaterials.2025.123347_bib29","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123347_bib30","article-title":"A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway","volume":"20","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biomaterials.2025.123347_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biomaterials.2025.123347_bib32","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.biomaterials.2025.123347_bib33","article-title":"Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms","author":"Takei","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biomaterials.2025.123347_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biomaterials.2025.123347_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1034\/j.1600-0609.2002.00551.x","article-title":"The splenic form of mantle cell lymphoma","volume":"68","author":"Angelopoulou","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib37","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2025.123347_bib38","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123347_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biocel.2017.11.011","article-title":"Splenomegaly: pathophysiological bases and therapeutic options","volume":"94","author":"McKenzie","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.biomaterials.2025.123347_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030898","article-title":"Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis","volume":"19","author":"Song","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2025.123347_bib41","doi-asserted-by":"crossref","first-page":"35989","DOI":"10.18632\/oncotarget.8540","article-title":"Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines","volume":"7","author":"Kobayashi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2025.123347_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-017-0652-8","article-title":"Smoldering mantle cell lymphoma","volume":"36","author":"Ye","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2025.123347_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130158","article-title":"Results from a phase 2 study of navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123347_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-137260","article-title":"Trial in progress: Phase Ib\/II study of Bcl-2\/Bcl-Xl inhibitor pelcitoclax (APG-1252) in patients with myelofibrosis (MF) that progressed after initial therapy","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123347_bib45","article-title":"A phase 3, double-blind, placebo-controlled, randomized study evaluating navitoclax in combination with ruxolitinib in patients with myelofibrosis (TRANSFORM-1)","volume":"136","author":"Potluri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2025.123347_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100798","article-title":"Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2\/Bcl-X(L) dual inhibitor that induces Bax-dependent apoptosis","volume":"29","author":"Yao","year":"2022","journal-title":"Neoplasia"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225002662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225002662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T20:12:53Z","timestamp":1748981573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961225002662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":46,"alternative-id":["S0142961225002662"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123347","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Albumin nanocomplex of BCL-2\/xL inhibitor reduced platelet toxicity and improved anticancer efficacy in myeloproliferative neoplasm and lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"123347"}}